IVIVA Medical

Executive Summary

IVIVA Medical is a biotechnology company developing a fully implantable bioartificial kidney as a curative treatment for end-stage renal disease (ESRD). As a subsidiary of United Therapeutics, the company leverages proprietary 3D printing and tissue engineering technologies to create human-scale, functional kidney grafts. This approach aims to address the critical organ shortage and free patients from lifelong dialysis dependency. The platform has the potential to transform the standard of care for over 2 million ESRD patients worldwide, offering a durable solution that mimics natural kidney function. With strong financial backing and expertise from United Therapeutics, IVIVA is advancing its preclinical pipeline toward first-in-human studies.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data publication80% success
• Q1 2027IND filing for first-in-human trial60% success
• Q4 2026Strategic partnership or licensing deal50% success